New therapeutic strategies with antiplatelet agents

Neurological Sciences

Volumn 25, Issue SUPPL. 1, 2004, Pages

  Micieli, Guiseppe ^a   Cavallini, A ^a  

^a C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

Author keywords

ADP receptor antagonists; Atherothrombosis; Clopidogrel

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; LOW MOLECULAR WEIGHT HEPARIN; TICLOPIDINE;

ATHEROMA; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; HEART DISEASE; HIGH RISK PATIENT; HUMAN; ISCHEMIA; ISCHEMIC HEART DISEASE; LONG TERM CARE; NONHUMAN; PROSTAGLANDIN SYNTHESIS INHIBITION; RECURRENT DISEASE; RESTENOSIS; THROMBOCYTE AGGREGATION INHIBITION; UNSTABLE ANGINA PECTORIS;

CEREBROVASCULAR ACCIDENT; CLINICAL TRIALS; DRUG THERAPY, COMBINATION; HUMANS; INTRACRANIAL ARTERIOSCLEROSIS; INTRACRANIAL THROMBOSIS; PLATELET AGGREGATION INHIBITORS; RECEPTORS, PURINERGIC P2; TREATMENT OUTCOME;

EID: 1642525860     PISSN: 15901874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10072-004-0209-4     Document Type: Conference Paper

References (17)

1. Nenci GG (1999) Unifying concept of arterial vascular disease. Eur Heart J 1 [Suppl A]:A27-A30
2. Hankey G (1998) The risk of vascular ischaemic events in patients with various clinical manifestations of atherothrmbosis: Data ftom CAPRIE. Cerebrovasc Dis 48[Suppl 4]:30
3. Hankey GJ, Jamrozik K, Broadhurst RJ, Forbes S, Burvill PW, Anderson CS, Stewart-Wynne EG (2000) Five-year survival after first-ever stroke and related prognostic factors in the Perth community Stroke Study. Stroke 31:2080-2086
4. Clark TG, Murphy MFG, Rothwell PM (2003) Long term risks of stroke, myocardial infarction, and vascular death in "lOw-risk" patients with a non-recent transient ischaemic attack. J Neurol Neurosurg Psychiatry 74:577-580
5. Hankey GJ, Sudlow CLM, Dunbabin DW (2000) Thienopyridines or aspirin to prevent stroke and other serious vascular events in patients at high risk of vascular disease? A systematic review of the evidence from randomised trials. Stroke 31:1779-1784
6. CAPRIE Steering Committee (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348:1329-1339
7. Ringleb PA, Bhatt DL, Hirsch AT, Topol EJ, Hacke W, for the CAPRIE Investigators (2004) Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events. Stroke 35:528-532
8. Bhatt DL, Marso SP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ (2000) Superiority of clopidogrel versus asipirn in patients with a history of diabetes mellitus. J Am Coll Cardiol 35[Suppl A):409
9. Bhatt DL, Foody J, Hirsch AT, Ringleb PA, Hacke W, Topol EJ (2000) Complementary, additive benefit of clopidogrel and lipid-lowering therapy in patients with atherosclerosis. J Am Coll Cardiol 35[Suppl A]:326.
10. Bhatt DL, Chew DP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ (2001) Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. Circulation 103:363-368
11. Hacke W (2003) From CURE to MATCH: ADP receptor antagonists as the treatment of choice for high-risk atherothrombotic patients. Cerebrovascular Dis 13[Suppl 1]:22-26
12. Cannon C (2002) Effectiveness of clopidogrel versus aspirin in preventing acute myocardial infarction in patients with symptomatic atherothrombosis (CAPRIE trial). Am J Cardiol 90:760-762
13. The Clopidogrel in Ustable angina to prevent Recurrent Events trial investigators (2001). Effects of clopidogrel addiction to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345:494-502
14. Steinhubl SR, Berger PB, Mann JT III, Fry ETA, DeLago A, Wilmer C, Topol EJ, for the CREDO Investigators (2002) Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. A randomized controlled trial. JAMA 288:2411-2420
15. Vane JR (1971) Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol 231:232-235
16. Moshfegh K, Redondo M, Julmy F, Wuillemin WA, Gebauer MU, Haeberli A, Meyer BJ (2000) Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction: Enhanced inhibitory effects of combination therapy. J Am Coll Cardiol 36:699-705
17. Levine RL, Dixit SN, Dulli DA, Khasru MA (2003) Aspirin "fAilures", CLOPIDOGREL added to Aspirin, and seconday stroke prevention in veterans presentino with TIA or mild-to-moderate ischemic stroke. J Stroke Cerebrovasc Dis 12:37-43